BioCentury This Week

BioCentury This Week

BioCentury

383 - Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

383 - Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
00:00
00:00

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Folgen

383-

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

Mo., 22 Jun. 2026
382-

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Mo., 15 Jun. 2026
381-

Ep. 371 - Moving faster at the academia-industry interface

Mi., 10 Jun. 2026
380-

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Mo., 08 Jun. 2026
379-

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Mo., 01 Jun. 2026